Positive interim review marks key milestone for POLB 001 clinical development 24 September 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the ongoing TOPICAL clinical trial will proceed as planned following a positive review of data from […]
More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona’s $86.6 million Series B financing Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, […]
Steven Kelly appointed Chief Executive Officer to lead Actithera through clinical development and continued pipeline expansion Briggs Morrison appointed Chair of the Board, bringing extensive biotech leadership and oncology drug development expertise John Crowley appointed Independent Director, adding proven strategic, financial and capital markets leadership Oslo, Norway and Cambridge, Massachusetts — 10 September 2026 — […]
Simris Group AB (publ) (“Simris” or the “Company”) confirms its strategy to develop amanitin-derived novel payloads to overcome treatment resistance in both liquid and solid tumors. Under strengthened specialist leadership, the Company will focus on advancing two proprietary Antibody-Drug Conjugate (“ADC”) programs into clinical development by late 2027 or early 2028. Read more…
Hammenhög, Sweden, July 28, 2026 — Simris Group AB (SIMRIS B) today announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor. Dr. Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organizations, and the broader innovation […]
